| Year |
N |
Methods |
Treatment |
Diagnostic modality |
% mucosal healing |
| D'Haens [44] |
1997 |
19 |
Cohort study |
AZA |
Ileocolonoscopy |
Complete or partial healing: 11 / 15 |
| D'Haens [45] |
1999 |
30 |
Multicenter, randomized, double-blind study |
IFX |
Ileocolonoscopy |
IFX: most.
Placebo: none. |
| D'Haens [39] |
1999 |
20 |
Retrospective study |
AZA |
Ileocolonoscopy |
Complete healing: 12/20 |
| Rutgeerts [46] |
2006 |
99 |
Subgroup of randomized, double-blind study |
IFX, scheduled vs. episodic treatment |
Ileocolonoscopy |
Responders (w2), scheduled: 50%
Episodic: 7% (p = 0.007) |
| Regueiro [47] |
2009 |
24 |
Prospective study |
IFX, prevention of postoperative recurrence |
Ileocolonoscopy, capsule endoscopy |
IFX: 84.6%
Placebo: 9.1%
(p< 0.01) |
| Schnitzler [43] |
2009 |
214 |
Retrospective study |
IFX, scheduled vs. episodic treatment |
Ileocolonoscopy |
Scheduled IFX: 76.9%
Episodic IFX: 61.0%
(p = 0.02 |
| Colombel [48] |
2010 |
508 |
Randomized, double-blind study |
IFX, AZA, IFX + AZA |
Ileocolonoscopy |
IFX + AZA: 43.9%
IFX: 30.1% (p=0.06)
AZA: 16.5% (p<0.05 |
| Baert [41] |
2010 |
49 |
Cohort of randomized study |
AZA + IFX vs. placebo |
Ileocolonoscopy |
Maintenance of remission with no therapy: 15/ 17 |
| Laharie [49] |
2011 |
51 |
Retrospective study |
MTX, AZA, or IFX |
Ileocolonoscopy |
MTX: 11%
AZA: 50% (p =0.011 vs. MTX)
IFX: 60% (p=0.008) |
